TrialCurve
Home / Trials

GENERATE: reconstructed Kaplan–Meier curves

Updated 2026-09-25 · reconstructed by TrialCurve from a CC BY-licensed publication

Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.

PublicationJ Clin Oncol. 2025 Jul 28;43(31):3345–54. doi: 10.1200/JCO.24.00936
DOI10.1200/JCO.24.00936
Registry—
Phase—
Conditions—
Interventions—
Sponsor—
Enrolment—
Source licenceFigure published under CC BY 4.0

Overall survival (planned interim analysis)

From figure panel A · validated against the values printed on the figure · curve source: vision model

Reconstructed from the published curve. Median: Nab-paclitaxel plus gemcitabine 17.1 months; Modified FOLFIRINOX 14.0 months; S-IROX 13.2 months. Survival at 12 months: Nab-paclitaxel plus gemcitabine 65%; Modified FOLFIRINOX 55%; S-IROX 60%. Hazard ratio Nab-paclitaxel plus gemcitabine vs S-IROX 0.74 (95% CI 0.55–1.00).

0%20%40%60%80%100%06121824303642MonthsNab-paclitaxel plus gemcitabinModified FOLFIRINOXS-IROX
ArmNEventsMedian (Months)
Nab-paclitaxel plus gemcitabine1418217.1
Modified FOLFIRINOX1439214.0
S-IROX1429313.2

Landmark survival (reconstructed)

TimeNab-paclitaxel plus gemcitabineModified FOLFIRINOXS-IROX
6 mo91.2%86.1%88.2%
12 mo64.6%54.6%59.6%
18 mo45.4%37.3%37.0%
24 mo29.7%24.5%23.9%
36 mo13.3%13.1%6.3%

Checks against the published figure

Download pseudo-IPD (CSV)

Overall survival (updated analysis)

From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: Nab-paclitaxel plus gemcitabine 17.0 months; Modified FOLFIRINOX 14.1 months; S-IROX 13.6 months. Survival at 12 months: Nab-paclitaxel plus gemcitabine 64%; Modified FOLFIRINOX 56%; S-IROX 60%. Hazard ratio Nab-paclitaxel plus gemcitabine vs S-IROX 0.79 (95% CI 0.60–1.04).

0%20%40%60%80%100%06121824303642MonthsNab-paclitaxel plus gemcitabinModified FOLFIRINOXS-IROX
ArmNEventsMedian (Months)
Nab-paclitaxel plus gemcitabine1769817.0
Modified FOLFIRINOX17510714.1
S-IROX17610613.6

Landmark survival (reconstructed)

TimeNab-paclitaxel plus gemcitabineModified FOLFIRINOXS-IROX
6 mo91.6%85.6%89.3%
12 mo64.5%55.6%60.0%
18 mo43.9%36.2%37.1%
24 mo29.8%24.1%24.6%
36 mo13.0%13.8%9.3%

Checks against the published figure

Download pseudo-IPD (CSV)

Progression-free survival

From figure panel C · validated against the values printed on the figure · curve source: vision model

Reconstructed from the published curve. Median: Nab-paclitaxel plus gemcitabine 6.9 months; Modified FOLFIRINOX 5.9 months; S-IROX 6.9 months. Survival at 12 months: Nab-paclitaxel plus gemcitabine 22%; Modified FOLFIRINOX 20%; S-IROX 20%. Hazard ratio Nab-paclitaxel plus gemcitabine vs Modified FOLFIRINOX 0.86 (95% CI 0.68–1.08).

0%20%40%60%80%100%06121824303642MonthsNab-paclitaxel plus gemcitabinModified FOLFIRINOXS-IROX
ArmNEventsMedian (Months)
Nab-paclitaxel plus gemcitabine1761326.9
Modified FOLFIRINOX1751485.9
S-IROX1761396.9

Landmark survival (reconstructed)

TimeNab-paclitaxel plus gemcitabineModified FOLFIRINOXS-IROX
6 mo55.8%49.1%51.0%
12 mo21.6%19.7%20.5%
18 mo14.1%11.2%12.5%
24 mo10.3%6.7%3.7%
36 mo4.1%3.7%2.5%

Checks against the published figure

Download pseudo-IPD (CSV)

About these data

Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.

Load these data in R or Python 
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/generate-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)

# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/generate-1.csv")
for arm, g in d.groupby("arm"):
    KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()

Suggested citation: J Clin Oncol. 2025 Jul 28;43(31):3345–54. doi: 10.1200/JCO.24.00936 doi:10.1200/JCO.24.00936. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/generate

Report a problem with these data

Related trials

Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.

Reconstruct a figure Browse all trials